Management of Mild Liver Fibrosis

Introduction to Treatment

The American Association for the Study of Liver Diseases recommends that treatment can often be deferred with close monitoring for patients with mild liver fibrosis (METAVIR F0-F1 or Ishak ≤2), as the prognosis without therapy is excellent and the urgency for treatment is lower than in patients with more advanced disease 1, 2

Treatment should be initiated promptly if the patient has significant fibrosis (METAVIR F2 or Ishak ≥3) 1, 2, 3
The European Association for the Study of the Liver suggests that treatment may be considered on a case-by-case basis for true mild fibrosis (F0-F1) when risk factors for fibrosis progression are present: age >40 years, male gender, metabolic syndrome, significant necroinflammatory activity, obesity, hepatic steatosis, or HIV coinfection 1, 4
The American Association for the Study of Liver Diseases recommends that treatment should generally be deferred when no or minimal fibrosis exists (METAVIR F0-F1 or Ishak ≤2) without risk factors for progression 1, 2

For HCV genotype 1 with mild fibrosis, the American Association for the Study of Liver Diseases suggests that treatment is often deferred unless favorable predictors exist (IL28B CC genotype with rapid virological response at week 4 achieves >90% sustained virological response) 4
For HCV genotypes 2 and 3, some experts advocate treating all patients regardless of fibrosis severity due to high response rates, potentially without requiring liver biopsy 1, 6

Annual monitoring is mandatory for patients with deferred treatment, including repeat non-invasive fibrosis assessment (FIB-4 score, transient elastography/FibroScan®, or serum fibrosis markers) 5, 4, 8
The American Association for the Study of Liver Diseases recommends that liver function tests and complete blood count should be performed annually 10

The FIB-4 score can be used for risk stratification, with a score <1.3 indicating low risk, 1.3-2.67 intermediate risk, and >2.67 high risk 9, 10
Transient elastography can also be used for risk stratification, with a value <8.0 kPa indicating low risk, 8.0-12.0 kPa intermediate risk, and >12.0 kPa high risk 9

The American Association for the Study of Liver Diseases warns that assuming normal ALT means no disease progression is incorrect, as 14-24% of patients with persistently normal ALT have more-than-portal fibrosis and may progress despite normal enzymes 1, 7
The European Association for the Study of the Liver emphasizes the importance of assessing for hepatocellular carcinoma risk in patients >40 years with cirrhosis or family history of HCC, regardless of fibrosis stage 8